Chlamydia Tests: Opportunity Assessments, Market Dynamics, Pipeline Analysis, H2 2018

Need more information?

Inquiry

We Offer You…

» Online support by email or telephone 24×7

» Assured confidentiality, safety and security as we operate through most trusted and reliable online payment systems

» Instant delivery of requested content in the desired form (PDF/PPT/Word Doc) to your provided email address after receiving the full payment.

» A Minimum Content Delivery initiation time of 9 hours

» An opportunity to be considered as an Expert Panel Member

» The provision of live, domain-specific updates

Chlamydia Tests: Opportunity Assessments, Market Dynamics, Pipeline Analysis, H2 2018

  • 192 Pages | 5-Jun-17 | Format:PDF | Last Updated: Updation in process

  • “GervanoRA’s pipeline analysis and opportunity assessment report “Chlamydia Tests: Opportunity Assessments, Market Dynamics, Pipeline Analysis, H2 2018” analyzed and assessed Chlamydia Tests pipeline devices for the opportunities in the competitive space by covering all the pipeline devices in different stages of development and all the companies which are actively involved in Chlamydia Tests industry. To provide systematic pipeline analytics, we have segregated total pipeline devices into different segments like Pipeline devices by Stage of development, Pipeline Devices by Equipment type, Pipeline devices by Regulatory class, Pipeline devices by Geography, and Pipeline devices by Regulatory path.
    Report is more focused to provide competitive opportunities by assessing and providing in-depth analytics on
    • Unmet needs and Opportunities
    • Epidemiology and Epidemiology forecast 2018 – 2025
    • Market Dynamics with Coverage of Deals (Mergers, Acquisitions, Partnering, Collaborations etc.)
    • Patent Analysis of Pipeline devices
    • Pipeline Analysis and Estimated Pipeline Device Approval Timelines
    • Clinical Trials Summary
    • Current and Future Competitive Landscape
    • Key Company Profiles with SWOT Analysis
    • Emerging Company Profiles with Opportunity Assessments
    • Pipeline Device Descriptions along with Development milestones (Past and Future)
    • University Pipeline Devices & In-Licensing/Out Licensing Opportunities
    Report helps clients to refine the commercial opportunities from the existing treatment armamentarium to pipeline assets, deals, and deal comparables. Even it helps in identifying the most relevant actors in the field for partnering deals.”

  • TABLE OF CONTENTS
    1. INTRODUCTION
    1.1. REPORT DESCRIPTION
    1.2. METHODOLOGY
    1.3. UPCOMING AND OTHER AVAILABLE PIPELINE ANALYSIS REPORTS
    1.4. ABOUT US: GERVANORA DATA SERVICES
    2. EXECUTIVE SUMMARY
    2.1. REPORT MAJOR FINDINGS
    2.2. KEY EVENTS IN CHLAMYDIA TESTS COMPETITIVE SPACE
    3. DISEASE OVERVIEW
    3.1. DISEASE DEFINITION & SYMPTOMS
    3.1.1. CLINICAL MANIFESTATIONS
    3.1.2. PATHOGENESIS
    3.2. DISEASE CAUSE AND CLASSIFICATION
    3.3. DISEASE DIAGNOSIS
    3.4. TREATMENT ALGORITHM AND GUIDELINES
    3.5. EPIDEMIOLOGY AND DISEASE BURDEN
    3.6. EPIDEMIOLOGY FORECAST
    3.6.1. FORECAST METHODOLOGY AND ASSUMPTION
    3.6.2. PROBABILISTIC EPIDEMIOLOGY FORECAST
    4. MARKET DYNAMICS
    4.1. GOVERNMENT REGULATORY DYNAMICS AND IMPACT
    4.2. PRICING AND REIMBURSEMENT
    4.3. DEALS (MERGERS/ ACQUISITIONS / COLLABORATIONS)
    4.4. PATENT ANALYSIS OF PIPELINE DEVICES
    4.5. NEW 510K APPROVALS SINCE 2010
    4.6. NEW PMA APPROVALS SINCE 2010
    4.7. NEW CE MARK APPROVALS SINCE 2010
    4.8. OTHER REGULATORY APPROVALS SINCE 2010
    5 PIPELINE ANALYSIS
    5.1. PIPELINE ANALYSIS BY STAGE OF DEVELOPMENT
    5.1.1. PHASE 3 PIPELINE DEVICES
    5.1.2. PHASE 2 PIPELINE DEVICES
    5.1.3. PHASE 1 PIPELINE DEVICES
    5.1.4. PRECLINICAL PIPELINE DEVICES
    5.1.5. EARLY R&D PIPELINE DEVICES
    5.1.6. INACTIVE AND DISCONTINUED PIPELINE DEVICES
    5.2. PIPELINE ANALYSIS BY GEOGRAPHY
    5.2.1. UNMET NEEDS AND OPPORTUNITIES
    5.3. PIPELINE ANALYSIS BY EQUIPMENT TYPE
    5.3.1. UNMET NEEDS AND OPPORTUNITIES
    5.4. PIPELINE ANALYSIS BY DEVICE CLASS
    5.4.1. UNMET NEEDS AND OPPORTUNITIES
    5.5. PIPELINE ANALYSIS BY REGULATORY PATH
    5.5.1. UNMET NEEDS AND OPPORTUNITIES
    5.6. PIPELINE ANALYSIS BY UNIVERSITIES AND INSTITUTES
    6 ESTIMATED APPROVAL TIMELINE
    6.1.1. METHODOLOGY
    6.1.2. ESTIMATED APPROVAL TIME LINES US & EX-US
    7. CHLAMYDIA TESTS CLINICAL TRIALS SUMMARY
    7.1. CHLAMYDIA TESTS PIPELINE ANALYSIS BY CLINICAL TRIALS RESULTS
    7.1.1. KEY PHASE 3 RESULTS
    7.1.2. KEY PHASE 2 RESULTS
    7.2. ONGOING CLINICAL TRIALS SUMMARY
    7.2.1 KEY PHASE 3 ONGOING CLINICAL TRIALS SUMMARY
    7.2.2 KEY PHASE 2 ONGOING CLINICAL TRIALS SUMMARY
    7.2.3. KEY PHASE 1 ONGOING CLINICAL TRIALS SUMMARY
    7.3. PLANNED CLINICAL TRIALS SUMMARY
    7.4. RECENTLY COMPLETED CLINICAL TRIALS SUMMARY
    7.4.1. RECENTLY COMPLETED PHASE 3 CLINICAL TRIALS SUMMARY
    7.4.2. RECENTLY COMPLETED PHASE 2 CLINICAL TRIALS SUMMARY
    7.4.3. RECENTLY COMPLETED PHASE 1 CLINICAL TRIALS SUMMARY
    8. CURRENT AND FUTURE COMPETITIVE LANDSCAPE
    8.1. COMPANIES
    8.1.1. ESTABLISHED COMPANY PROFILES WITH SWOT ANALYSIS
    8.2. TOP 20 EMERGING COMPANIES IN THE CHLAMYDIA TESTS WITH PRODUCT DESCRIPTIONS AND MILESTONES
    8.3. UNIVERSITIES AND INSTITUTES – LICENSING OPPORTUNITIES
    9. ABBREVIATIONS
    LIST OF TABLES:
    TABLE 01: REPORT HIGHLIGHTS IN NUMERICALS
    TABLE 02: DISEASE EPIDEMIOLOGY (2017), FORECAST (2018-2025) IN MILLIONS
    TABLE 03: MAJOR COLLABORATIVE AGREEMENTS IN THE CHLAMYDIA TESTS
    TABLE 04: MAJOR LICENSING AGREEMENTS IN THE CHLAMYDIA TESTS
    TABLE 05: MAJOR MERGERS AND ACQUISITIONS IN THE CHLAMYDIA TESTS
    TABLE 06: MAJOR ALLIANCE AGREEMENTS IN THE CHLAMYDIA TESTS
    TABLE 07: MAJOR FINANCING DEALS IN THE CHLAMYDIA TESTS
    TABLE 08: MAJOR DEALS IN THE CHLAMYDIA TESTS RANKED BY DEAL AMOUNT
    TABLE 09: 510K APPROVED DEVICES SINCE 2010
    TABLE 10: PMA APPROVED DEVICES SINCE 2010
    TABLE 11: CE MARK APPROVED DEVICES SINCE 2010
    TABLE 12: DEVICES APPROVED BY OTHER REGULATORY BODIES SINCE 2010
    TABLE 13: PHASE 3 DEVICES IN THE CHLAMYDIA TESTS PIPELINE
    TABLE 14: PHASE 2 DEVICES IN THE CHLAMYDIA TESTS PIPELINE
    TABLE 15: PHASE 1 DEVICES IN THE CHLAMYDIA TESTS PIPELINE
    TABLE 16: PRECLINICAL DEVICES IN THE CHLAMYDIA TESTS PIPELINE
    TABLE 17: EARLY R&D DEVICES IN THE CHLAMYDIA TESTS PIPELINE
    TABLE 18: INACTIVE AND DISCONTINUED DEVICES IN THE CHLAMYDIA TESTS PIPELINE
    TABLE 19: CHLAMYDIA TESTS PIPELINE DEVICES OVERVIEW BY DEVICE CLASS
    TABLE 20: CHLAMYDIA TESTS PIPELINE DEVICES OVERVIEW BY REGULATORY PATH
    TABLE 21: CHLAMYDIA TESTS PIPELINE DEVICES BY UNIVERSITIES
    TABLE 22: CHLAMYDIA TESTS PIPELINE DEVICES BY INSTITUTES
    TABLE 23: ESTIMATED APPROVAL Time lines OF PIPELINE DEVICES
    TABLE 24: KEY PHASE 3 ONGOING CLINICAL TRIALS
    TABLE 25: KEY PHASE 2 ONGOING CLINICAL TRIALS
    TABLE 26: KEY PHASE 1 ONGOING CLINICAL TRIALS
    TABLE 27: PLANNED CLINICAL TRIALS FOR THE CHLAMYDIA TESTS
    TABLE 28: RECENTLY COMPLETED PHASE 3 CLINICAL TRIALS
    TABLE 29: RECENTLY COMPLETED PHASE 2 CLINICAL TRIALS
    TABLE 30: RECENTLY COMPLETED PHASE 1 CLINICAL TRIALS
    TABLE 31: ESTABLISHED COMPANIES SCENARIO
    TABLE 32: LIST OF EMERGING COMPANIES IN THE CHLAMYDIA TESTS
    TABLE 33: COMPETITIVE OPPORTUNITIES, UNIVERSITIES
    TABLE 34: COMPETITIVE OPPORTUNITIES, INSTITUTES
    (Above mentioned tables are a few among the total 87 tables in the report)
    LIST OF FIGURES:
    FIGURE 01: KEY PIPELINE EVENTS, 2019-2029
    FIGURE 02: CHLAMYDIA TESTS EPIDEMIOLOGY (2017), FORECAST (2018- 2025) IN MILLIONS
    FIGURE 03: OVERALL DEALS ACTIVITY IN THE CHLAMYDIA TESTS
    FIGURE 04: OVERALL DEAL FINANCING ACTIVITY V/S DEAL TYPE
    FIGURE 05: GEOGRAPHY WISE BREAK UP V/S DEAL TYPE
    FIGURE 06: CHLAMYDIA TESTS DEVICE PIPELINE ANALYSIS BY STAGES OF DEVELOPMENT
    FIGURE 07: CHLAMYDIA TESTS DEVICE PIPELINE ANALYSIS BY GEOGRAPHY
    FIGURE 08: CHLAMYDIA TESTS DEVICE PIPELINE ANALYSIS BY STAGES OF DEVELOPMENT V/S GEOGRAPHIES
    FIGURE 09: CHLAMYDIA TESTS DEVICE PIPELINE ANALYSIS BY DEVICE CLASS
    FIGURE 10: CHLAMYDIA TESTS DEVICE PIPELINE ANALYSIS BY REGULATORY PATH
    FIGURE 11: CHLAMYDIA TESTS DEVICE MOLECULES DEVELOPED BY UNIVERSITIES AND INSTITUTES
    FIGURE 12: ONGOING CLINICAL TRIALS SPLIT-UP BY HSD
    FIGURE 13: RECENTLY COMPLETED CLINICAL TRIALS SPLIT-UP BY HSD
    FIGURE 14: RECENTLY COMPLETED CLINICAL TRIALS SPLIT-UP BY MAJOR COMPANIES
    FIGURE 15: COMPANY FINANCIAL INFORMATION
    FIGURE 16: COMPANY SWOT ANALYSIS (Above mentioned Figures are a few among the total 45 Figures in the report)

Pricing

Individual Pricing $2500

Corporate Pricing $2500

Enterprise Pricing $2500

(We are offering all the above license types for a single price!!)